Update on Lupus Nephritis
DOI:
https://doi.org/10.58931/crt.2024.1143Abstract
Lupus Nephritis (LN) is a common and severe manifestation of systemic lupus erythematosus (SLE), impacting up to 40% of SLE patients. Despite advancements in understanding the pathogenesis of LN, outcomes have not significantly improved since the early 2000s. LN patients face higher mortality, emphasizing the importance of achieving disease remission. Screening for nephritis involves regular monitoring, especially within the first 5 years of SLE diagnosis. Monitoring includes urinalysis, serum creatinine, and immune serology. Kidney biopsy remains the gold standard for LN diagnosis and classification, providing crucial information for treatment decisions. The standard of care involves hydroxychloroquine for all LN patients, with immunosuppressive treatments tailored to the histologic class. The recently approved medications, belimumab and voclosporin, offer additional therapeutic alternatives. Approximately 20% of LN patients exhibit features of thrombotic microangiopathy, warranting anticoagulation. Optimizing glucocorticoid dosing is recommended, favouring lower doses to minimize adverse effects. Lifelong monitoring is essential, as flares can occur at any point, emphasizing the need for continued immunosuppression.
Given the lack of renal response in 30–60% of patients, the addition of combination therapies, such as calcineurin inhibitors or belimumab, should be considered. Duration of treatment is crucial, considering the progressive loss of podocytes and nephron function, which may lead to chronic kidney disease. Regular monitoring, maintenance immunosuppression, and lifestyle modifications contribute to preventing flares and improving long-term outcomes for LN patients.
References
Pryor KP, Barbhaiya M, Costenbader KH, Feldman CH. Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries. Rheum Dis Clin North Am. 2021;47(1):41-53. DOI: https://doi.org/10.1016/j.rdc.2020.09.004
Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023;4(10):1503-11. DOI: https://doi.org/10.34067/KID.0000000000000230
Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971- 2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016;68(6):1432-41. DOI: https://doi.org/10.1002/art.39594
Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-62. DOI: https://doi.org/10.1093/rheumatology/kev311
Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-35. DOI: https://doi.org/10.2215/CJN.05780616
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-31. DOI: https://doi.org/10.1002/art.10461
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12. DOI: https://doi.org/10.1681/ASN.2008101028
Matsos M, Clarke A, Keeling S, Peschken C, Touma Z, Tselios K, et al. Appropriate Screening and Management of Lupus Nephritis. Canadian Institute for the Transfer of Knowledge; 2023.
Mok CC, Teng YKO, Saxena R, Tanaka Y. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol. 2023;19(4):227-38. DOI: https://doi.org/10.1038/s41584-023-00925-5
Fanouriakis A, Bertsias G, Liapis G, Marinaki S, Papagianni A, Stangou M, et al. Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents. Lupus. 2023;32(10):1155-63. DOI: https://doi.org/10.1177/09612033231191944
Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-96. DOI: https://doi.org/10.1016/j.kint.2017.11.023
Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76(2):265-81. DOI: https://doi.org/10.1053/j.ajkd.2019.10.017
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-23. DOI: https://doi.org/10.1136/annrheumdis-2020-216924
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2023. DOI: https://doi.org/10.1136/ard-2024-226636
Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupusnephritis management renaissance. Kidney Int. 2022;101(2):242-55. DOI: https://doi.org/10.1016/j.kint.2021.09.012
Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90(3):493-501 DOI: https://doi.org/10.1016/j.kint.2016.05.017
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Rheumatology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
